Certified Clinical Research Coordinator (CCRC) Practice Test

The ACRP Certified Clinical Research Coordinator (CCRC) certification is designed for professionals who can manage the day-to-day responsibilities of a clinical trial while maintaining the highest standards of participant safety, regulatory compliance, and data quality. Passing the exam requires more than remembering research terminology or regulatory guidelines—it requires the ability to apply those principles in situations that Clinical Research Coordinators encounter every day.

From screening and informed consent to investigational product accountability, adverse event reporting, protocol compliance, and study closeout, the exam measures your judgment across the entire clinical trial process. You’ll be expected to recognize the correct course of action, prioritize participant welfare, interpret study requirements accurately, and make decisions that align with ICH Good Clinical Practice (GCP), FDA regulations, and accepted research standards.

This ACRP CCRC Practice Test has been developed to reflect those real-world expectations. Instead of relying on straightforward recall questions, it challenges you with practical scenarios that mirror the types of issues Clinical Research Coordinators routinely manage at research sites. Each question is paired with a detailed explanation that helps you understand not only the correct answer, but also the reasoning behind it.

As you work through the practice questions, you’ll strengthen your understanding of informed consent, participant eligibility, protocol deviations, safety reporting, source documentation, electronic data capture (EDC), investigational product management, monitoring visits, regulatory inspections, decentralized clinical trials, quality management, and many other core responsibilities covered on the CCRC exam.

Whether you work in pharmaceutical research, biotechnology, medical devices, hospitals, academic research centers, contract research organizations (CROs), or independent clinical research sites, this study resource is designed to help you build the confidence, clinical judgment, and regulatory knowledge needed to approach the ACRP CCRC certification exam with confidence.

What’s Included

• 750+ high-quality CCRC practice questions
• Detailed answer explanations for every question
• Scenario-based and case-study format similar to the certification exam
• Coverage of current ICH Good Clinical Practice principles
• FDA regulations and human subject protection topics
• Clinical trial operations from study startup through closeout
• Unlimited practice attempts
• Instant online access
• Mobile, tablet, and desktop compatible
• Regular content updates

Topics Covered

This comprehensive CCRC practice test covers the knowledge domains commonly evaluated on the certification exam, including:

• Clinical research regulations and ethics
• ICH E6 Good Clinical Practice (GCP)
• FDA regulations and investigator responsibilities
• Human subject protection
• Informed consent and reconsent
• Institutional Review Board (IRB) requirements
• Participant recruitment and retention
• Eligibility assessment and screening
• Randomization and blinding
• Clinical trial protocol implementation
• Source documentation and ALCOA+ principles
• Electronic Data Capture (EDC)
• Electronic source documentation (eSource)
• Adverse Events (AE)
• Serious Adverse Events (SAE)
• Safety reporting requirements
• Investigational product management
• Drug accountability and temperature monitoring
• Laboratory specimen collection and handling
• Imaging procedures
• Medical device studies
• Data quality and query resolution
• Monitoring visits
• Audit and inspection readiness
• Risk-based monitoring
• Protocol deviations and CAPA
• Essential documents and Trial Master File (TMF)
• Investigator oversight and delegation logs
• Clinical trial quality management
• Vendor oversight
• Decentralized clinical trials
• Telehealth research visits
• Participant confidentiality and HIPAA
• Study closeout procedures

Why Choose This ACRP CCRC Practice Test?

The CCRC examination measures your ability to apply clinical research principles—not simply recall definitions. Questions often require you to evaluate participant scenarios, interpret protocol requirements, prioritize safety, and determine the most appropriate regulatory action.

This practice exam mirrors that approach by presenting realistic situations that Clinical Research Coordinators face throughout the life cycle of a clinical trial. Instead of relying on repetitive recall questions, you’ll develop the judgment needed to make confident decisions under exam conditions.

As you progress through the question bank, you’ll strengthen your understanding of:

• Clinical trial coordination
• Regulatory compliance
• Participant safety
• Research ethics
• Data integrity
• Study documentation
• Risk management
• Investigator responsibilities
• Quality assurance
• Inspection readiness

Each explanation goes beyond identifying the correct answer by explaining why the other options are less appropriate. This reinforces key concepts and helps you understand how regulations apply in practical clinical research settings.

Who Should Use This Practice Test?

This resource is ideal for:

• Clinical Research Coordinators preparing for ACRP certification
• Assistant Clinical Research Coordinators
• Clinical Research Associates (CRAs)
• Research Nurses
• Clinical Trial Coordinators
• Research Assistants
• Site Managers
• Regulatory Coordinators
• Clinical Project Coordinators
• Academic research professionals
• Healthcare professionals transitioning into clinical research
• Individuals seeking careers in pharmaceutical, biotechnology, or medical device research

Whether you’re taking the CCRC exam for the first time or preparing for recertification, this practice test provides structured preparation that supports both knowledge retention and exam confidence.

Build Confidence Before Exam Day

Certification demonstrates your commitment to high-quality clinical research and professional excellence. Effective preparation should strengthen both your understanding of regulatory requirements and your ability to apply them consistently in complex situations.

This ACRP Certified Clinical Research Coordinator Practice Test gives you the opportunity to practice with realistic questions, identify knowledge gaps, improve clinical reasoning, and become familiar with the style and complexity of the certification exam. By practicing across a broad range of clinical research topics, you’ll be better prepared to approach the exam with confidence and perform at your best.

CCRC Sample Questions and Answers

Question: A coordinator is screening a participant for a diabetes clinical trial. During the screening visit, the participant’s fasting blood glucose result exceeds the protocol’s exclusion threshold by a small margin. The participant insists the result is unusually high because they accidentally ate breakfast before the blood draw.

What is the MOST appropriate action?

A. Enroll the participant because the explanation seems reasonable.

B. Ask the laboratory to change the reported value.

C. Follow the protocol regarding repeat testing, if permitted, and consult the principal investigator before making an eligibility decision.

D. Ignore the laboratory result and use the participant’s previous clinic records.

Correct Answer: C

Explanation:

Eligibility decisions must always follow the approved protocol rather than assumptions or participant preferences. If the protocol allows a repeat fasting laboratory assessment, the coordinator should arrange the repeat test according to protocol requirements after consulting the principal investigator. Documentation should clearly explain why repeat testing was performed. Coordinators should never alter laboratory values or selectively use outside medical records to qualify an otherwise ineligible participant. Maintaining objective eligibility standards protects participant safety, ensures scientific validity, and preserves regulatory compliance during sponsor audits and FDA inspections.

Question: A participant arrives for a scheduled study visit but realizes they forgot to take the required study diary home after the previous visit. Consequently, symptom information for the past two weeks is unavailable.

What should the coordinator do?

A. Complete the diary from memory on behalf of the participant.

B. Leave the diary blank without documenting the issue.

C. Document the missing data, notify the investigator if required, and follow protocol guidance regarding missing participant-reported outcomes.

D. Estimate the missing responses using previous visits.

Correct Answer: C

Explanation:

Missing participant-reported data should never be fabricated or estimated. The coordinator should accurately document why the information is unavailable, follow study-specific procedures, and determine whether the missing data constitute a protocol deviation. Transparency is essential because sponsors and regulatory authorities understand that missing data occasionally occur, but undocumented or fabricated information seriously threatens research credibility. Coordinators should also educate participants on the importance of completing study diaries and discuss strategies to improve compliance during future visits.

Question:

A research participant enrolled in a Phase III clinical trial experiences severe chest pain two days after receiving the investigational medication. The participant is admitted to the hospital, and the principal investigator believes the event may be related to the study drug.

What should the clinical research coordinator do FIRST?

A. Wait until the participant is discharged before documenting the event.

B. Report the event according to the protocol and sponsor reporting requirements while ensuring participant safety.

C. Notify future study participants that a serious adverse event has occurred.

D. Remove the participant from the study without consulting the investigator.

Correct Answer: B

Explanation:

Participant safety is always the highest priority in clinical research. When a serious adverse event (SAE) occurs, the clinical research coordinator should immediately assist the investigator in ensuring appropriate medical care while documenting and reporting the event according to the study protocol, sponsor requirements, IRB policies, and applicable regulations. Timely reporting allows sponsors and regulators to evaluate whether the investigational product presents additional risks to participants. Waiting until discharge delays required reporting, and participants should never be withdrawn without investigator assessment. Informing other participants is not automatically required unless approved revised consent information becomes necessary.

Question: Which document BEST demonstrates that a site has delegated specific study responsibilities to qualified research staff?

A. Investigator brochure

B. Delegation of authority log

C. Financial disclosure form

D. Drug accountability log

Correct Answer: B

Explanation:

The delegation of authority log identifies each study team member, documents assigned responsibilities, and confirms that delegated duties are appropriate for each individual’s qualifications and training. During inspections and monitoring visits, this document helps demonstrate regulatory compliance and confirms that only authorized personnel performed study activities. While the investigator brochure provides scientific information and the drug accountability log tracks investigational product inventory, neither establishes delegated responsibilities for site personnel.

Question: A participant signs the informed consent form before any study procedures begin. During the coordinator’s review, it is discovered that the participant forgot to initial one required page of the IRB-approved consent document.

What is the MOST appropriate action?

A. Add the participant’s initials after they leave the clinic.

B. Ask another staff member to initial the page.

C. Have the participant complete the missing initial as soon as possible, document the correction according to site policy, and ensure the consent process remains fully documented.

D. Destroy the consent form and pretend consent never occurred.

Correct Answer: C

Explanation:

Minor documentation omissions should be corrected by the individual who made the omission whenever possible. The participant—not the coordinator or another staff member—should provide the missing initial. The coordinator should document the correction according to institutional policy, ensuring transparency and preserving the audit trail. If there is any concern that the participant did not receive adequate information before consenting, the investigator should reassess the informed consent process. Regulatory agencies expect complete, accurate, and contemporaneous consent documentation because informed consent is one of the most frequently reviewed aspects during inspections.

Question: During a follow-up phone call, a participant reports mild dizziness after taking the investigational medication but says the symptom resolved within one hour and did not require medical treatment.

How should the coordinator classify this event?

A. Ignore the symptom because it resolved.

B. Document it as an adverse event and assess severity, duration, and relationship to the investigational product.

C. Report it only if hospitalization occurs.

D. Record it only at study closeout.

Correct Answer: B

Explanation:

An adverse event includes any unfavorable medical occurrence after study participation, regardless of whether it is believed to be caused by the investigational product. Even mild, self-limited symptoms should be documented according to protocol requirements. The investigator determines the severity and relationship to the investigational product. Consistent documentation allows sponsors to identify safety trends across all study sites. Failure to report seemingly minor events may delay recognition of emerging safety signals that become apparent only after reviewing data from many participants.

Question: The sponsor distributes Protocol Amendment Version 5.0. Your site is currently conducting participant visits under Version 4.0.

Before implementing the amendment under normal circumstances, the coordinator should FIRST verify:

A. That every participant prefers the new protocol.

B. IRB approval, investigator acknowledgment, staff training, and sponsor implementation instructions.

C. That the amendment shortens study visits.

D. That participants are willing to pay additional travel expenses.

Correct Answer: B

Explanation:

Protocol amendments usually require IRB review and approval before implementation unless immediate participant safety concerns justify earlier action. Coordinators should confirm that regulatory approval has been received, investigators have acknowledged the amendment, study staff have completed training, revised informed consent forms have been approved if necessary, and sponsor implementation instructions have been followed. Careful transition planning helps ensure consistent study conduct and minimizes protocol deviations after new study requirements become effective.

Question: A sponsor is preparing the final Clinical Study Report for a large international Phase III trial. During the site’s final document reconciliation, the coordinator identifies the following:

• All participants completed follow-up.
• Database is locked.
• Serious adverse event reconciliation is complete.
• Drug accountability is complete.
• Trial Master File is complete.
• One protocol deviation identified six months earlier was documented internally but never reported to the sponsor, although the protocol required sponsor notification.

What is the MOST appropriate action?

A. Ignore the issue because database lock has already occurred.

B. Notify the principal investigator immediately, inform the sponsor according to applicable procedures, document the delayed reporting honestly, evaluate whether corrective and preventive actions (CAPA) are necessary, and retain all documentation.

C. Remove the protocol deviation from the site files.

D. Create a new deviation report using the original reporting date.

Correct Answer: B

Explanation:

Even after database lock, regulatory responsibilities continue. Failure to report a protocol deviation according to sponsor requirements should be addressed transparently rather than concealed. The coordinator should immediately notify the principal investigator, submit the required documentation, explain the delayed reporting accurately, and participate in a root cause analysis to determine why the reporting failure occurred. Appropriate corrective and preventive actions may include staff retraining, revised reporting workflows, or additional quality reviews. Honest documentation demonstrates integrity and supports regulatory compliance far more effectively than attempting to alter historical records or conceal errors.

Question: During an FDA inspection, the inspector requests the signed Site Signature and Delegation Log. While searching the regulatory binder, the coordinator realizes the current version cannot be located.

What is the MOST appropriate action?

A. Create a new delegation log using today’s date and ask staff to sign it.

B. Inform the inspector and principal investigator immediately, search all approved filing locations, determine whether the document exists elsewhere, document the investigation, and implement corrective actions if the document cannot be recovered.

C. Borrow another study site’s delegation log.

D. Remove all delegation documentation from the inspection room.

Correct Answer: B

Explanation:

Essential documents must be maintained throughout the clinical trial and remain readily available during inspections. If a required document cannot be located, coordinators should honestly inform the investigator and inspector while conducting a documented search. Creating replacement records that falsely represent historical events is considered data falsification. The investigation should determine whether the document was misfiled, archived incorrectly, or never completed. Corrective and Preventive Actions (CAPA) should address weaknesses in document control to prevent future occurrences. Regulatory agencies generally view transparent documentation more favorably than attempts to conceal deficiencies.